TY - JOUR
T1 - Use of verbal autopsy to determine underlying cause of death during treatment of multidrug-resistant Tuberculosis, India
AU - Naik, Poonam Ramesh
AU - Moonan, Patrick K.
AU - Nirgude, Abhay Subhashrao
AU - Shewade, Hemant Deepak
AU - Satyanarayana, Srinath
AU - Raghuveer, Pracheth
AU - Parmar, Malik
AU - Ravichandra, Chinnappareddy
AU - Singarajipura, Anil
N1 - Funding Information:
The study was conducted as a part of the National Operational Research Training Course, 2016. This training project was conceived and implemented jointly by Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India; the National TB Institute, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India Bangalore, India; the International Union Against Tuberculosis and Lung Diseases, South-East Asia Regional Office, New Delhi, India; and the Division of Global HIV and TB, Center for Global Health, US Centers for Disease Control and Prevention. This study was funded by the International Union Against Tuberculosis and Lung Diseases (South-East Asia Regional Office, New Delhi, India). The travel costs associated with data collection were funded by Yenepoya University, Mangalore, Karnataka, India.
Funding Information:
We thank all of the proxies and families who had the courage to participate in our research during a time of mourning, grief, and personal loss. We thank the state TB officer, district TB officers, and program staff of the districts and DR-TB centers who facilitated this study. We are indebted to our independent committee members for their time and expertise during the verbal autopsy review and deliberation: Prabha Adhikari, K.M. Akshaya, Deepu Chengappa. Special thanks to Viquar Ahmed, K.R. Nischith, and Reshma Acharya for their assistance with data acquisition and local coordination and to James Tobias for cartographic assistance. The study was conducted as a part of the National Operational Research Training Course, 2016. This training project was conceived and implemented jointly by Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India; the National TB Institute, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India Bangalore, India; the International Union Against Tuberculosis and Lung Diseases, South-East Asia Regional Office, New Delhi, India; and the Division of Global HIV and TB, Center for Global Health, US Centers for Disease Control and Prevention. This study was funded by the International Union Against Tuberculosis and Lung Diseases (South-East Asia Regional Office, New Delhi, India). The travel costs associated with data collection were funded by Yenepoya University, Mangalore, Karnataka, India.
Publisher Copyright:
© 2018, Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2018/3
Y1 - 2018/3
N2 - Of patients with multidrug-resistant tuberculosis (MDR TB), <50% complete treatment. Most treatment failures for patients with MDR TB are due to death during TB treatment. We sought to determine the proportion of deaths during MDR TB treatment attributable to TB itself. We used a structured verbal autopsy tool to interview family members of patients who died during MDR TB treatment in India during January– December 2016. A committee triangulated information from verbal autopsy, death certificate, or other medical records available with the family members to ascertain the underlying cause of death. For 66% of patient deaths (47/71), TB was the underlying cause of death. We assigned TB as the underlying cause of death for an additonal 6 patients who died of suicide and 2 of pulmonary embolism. Deaths during TB treatment signify program failure; accurately determining the cause of death is the first step to designing appropriate, timely interventions to prevent premature deaths.
AB - Of patients with multidrug-resistant tuberculosis (MDR TB), <50% complete treatment. Most treatment failures for patients with MDR TB are due to death during TB treatment. We sought to determine the proportion of deaths during MDR TB treatment attributable to TB itself. We used a structured verbal autopsy tool to interview family members of patients who died during MDR TB treatment in India during January– December 2016. A committee triangulated information from verbal autopsy, death certificate, or other medical records available with the family members to ascertain the underlying cause of death. For 66% of patient deaths (47/71), TB was the underlying cause of death. We assigned TB as the underlying cause of death for an additonal 6 patients who died of suicide and 2 of pulmonary embolism. Deaths during TB treatment signify program failure; accurately determining the cause of death is the first step to designing appropriate, timely interventions to prevent premature deaths.
UR - http://www.scopus.com/inward/record.url?scp=85042307401&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042307401&partnerID=8YFLogxK
U2 - 10.3201/eid2403.171718
DO - 10.3201/eid2403.171718
M3 - Article
C2 - 29460737
AN - SCOPUS:85042307401
SN - 1080-6040
VL - 24
SP - 478
EP - 484
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 3
ER -
